The trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with malignant ascites: Immunomonitoring results of a pivotal phase II/III study (pooled population)

被引：0
|
作者：
Jaeger, M.
Schoberth, A.
Hennig, M.
Burges, A.
Heiss, M.
Wimberger, P.
Schmalfeldt, B.
Lindhofer, H.
机构：
[1] TRION Res GmbH, Martinsried, Germany
[2] Fresenius Biotech GmbH, Munich, Germany
[3] Univ Munich, Dept Gynecol & Obstet, Munich, Germany
[4] Univ Cologne Witten Herdecke, Dept Surg, Cologne, Germany
[5] AGO, Essen, Germany
[6] AGO, Munich, Germany
[7] TRION Pharma GmbH, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2521
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Treatment of peritoneal carcinomatosis due to GI-tract cancer by intraperitoneal application of the trifunctional antibody catumaxomab (anti-EpcAM x anti-CD3): Results of a phase VII trial.
    Stroehlein, MA
    Lordick, F
    Ruettinger, D
    Gruetzner, U
    Menzel, H
    Bartelheim, K
    Jaeger, M
    Lindhofer, H
    Jauch, KW
    Peschel, C
    Heiss, MM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 173S - 173S
  • [22] Elimination of cancer stem cells (CD133+/EpCAM+) from malignant ascites by the trifunctional antibody catumaxomab: Results from a pivotal phase II/III study
    Lindhofer, H.
    Schoberth, A.
    Pelster, D.
    Hess, J.
    Herold, J.
    Jaeger, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
    Maren Knödler
    Justus Körfer
    Volker Kunzmann
    Jörg Trojan
    Severin Daum
    Michael Schenk
    Frank Kullmann
    Sebastian Schroll
    Dirk Behringer
    Michael Stahl
    Salah-Eddin Al-Batran
    Ulrich Hacker
    Stefan Ibach
    Horst Lindhofer
    Florian Lordick
    British Journal of Cancer, 2018, 119 : 296 - 302
  • [24] Different mechanisms of action contribute to the cytotoxic efficacy of catumaxomab (anti-EpCAM x anti-CD3) in vitro
    Lindemann, Carsten
    Schroeder, Petra
    Atz, Judith
    Dettmar, Kirsten
    Kluge, Michael
    CANCER RESEARCH, 2009, 69
  • [25] Putative cancer stem cells (CD133+/EpCAM+) are eliminated from malignant ascites by the trifunctional antibody catumaxomab: results from a pivotal Phase II/III study
    Lindhofer, H.
    Schoberth, A.
    Pelster, D.
    Hess, J.
    Herold, J.
    Stroehlein, M.
    Jaeger, M.
    ONKOLOGIE, 2010, 33 : 157 - 157
  • [26] An anti-EpCAM x anti-CD3 bispecific antibody, M701, for the treatment of malignant ascites due to epithelial cancer: Interim results of a prospective randomized controlled phase II trial
    Lin, Rongbo
    Xu, Jianming
    Liu, Rongrui
    Li, Ning
    Li, Guiling
    Zhang, Tao
    Zhao, Jun
    Li, Jiayi
    Sun, Meili
    Wang, Ke
    An, Hanxiang
    Zhang, Weijie
    Xu, Huiting
    Zeng, Shan
    Zhang, Mingjun
    Zhou, Pengfei
    Huang, Shaoyi
    Wang, Xiong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] CONTRIBUTION OF IMMUNOGENIC CELL DEATH (ICD) TO THE ANTI-TUMOR ACTIVITY OF CATUMAXOMAB (ANTI-EPCAM X ANTI-CD3)
    Goere, D.
    Flament, C.
    Chaput-Gras, N.
    Zitvogel, L.
    ANNALS OF ONCOLOGY, 2012, 23 : 169 - 170
  • [28] Intraperitoneal immunotherapy with the bispecific anti-EpCAM x anti-CD3 directed antibody catumaxomab for patients with peritoneal carcinomatosis from gastric cancer: Final results of a randomized phase II AIO trial.
    Lordick, Florian
    Kunzmann, Volker
    Trojan, Jorg
    Daum, Severin
    Schenk, Michael
    Kullmann, Frank
    Schroll, Sebastian
    Behringer, Dirk M.
    Stahl, Michael
    Al-Batran, Salah-Eddin
    Ibach, Stefan
    Koerfer, Justus
    Knoedler, Maren Kristina
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [29] Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: Results of a phase II/III study
    Parsons, S. L.
    Kutarska, E.
    Koralewski, P.
    Gore, M.
    Wimberger, P.
    Burges, A.
    Stroehlein, M. A.
    Lahr, A.
    Jaeger, M.
    Heiss, M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo
    Dettmar, Kirsten
    Seitz-Merwald, Isabell
    Lindemann, Carsten
    Schroeder, Petra
    Seimetz, Diane
    Atz, Judith
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (05): : 376 - 381
12345